IL130839A - Inhalation preparation with an ejaculation density of between 0.28 and 0.38 g / ml containing trabutlin sulfate Process for the preparation and use of the preparation - Google Patents

Inhalation preparation with an ejaculation density of between 0.28 and 0.38 g / ml containing trabutlin sulfate Process for the preparation and use of the preparation

Info

Publication number
IL130839A
IL130839A IL13083998A IL13083998A IL130839A IL 130839 A IL130839 A IL 130839A IL 13083998 A IL13083998 A IL 13083998A IL 13083998 A IL13083998 A IL 13083998A IL 130839 A IL130839 A IL 130839A
Authority
IL
Israel
Prior art keywords
composition according
formulation
bulk density
described hereinabove
carrier substance
Prior art date
Application number
IL13083998A
Other languages
English (en)
Hebrew (he)
Other versions
IL130839A0 (en
Inventor
Jan Trofast
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of IL130839A0 publication Critical patent/IL130839A0/xx
Publication of IL130839A publication Critical patent/IL130839A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
IL13083998A 1997-01-20 1998-01-13 Inhalation preparation with an ejaculation density of between 0.28 and 0.38 g / ml containing trabutlin sulfate Process for the preparation and use of the preparation IL130839A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9700136A SE9700136D0 (sv) 1997-01-20 1997-01-20 New formulation
PCT/SE1998/000041 WO1998031353A1 (fr) 1997-01-20 1998-01-13 Nouvelle formulation pour inhalation ayant une densite en vrac de 0,28 a 0,38 g/ml et contenant du sulfate de terbutaline, procede de preparation et utilisation de cette formulation

Publications (2)

Publication Number Publication Date
IL130839A0 IL130839A0 (en) 2001-01-28
IL130839A true IL130839A (en) 2004-12-15

Family

ID=20405456

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13083998A IL130839A (en) 1997-01-20 1998-01-13 Inhalation preparation with an ejaculation density of between 0.28 and 0.38 g / ml containing trabutlin sulfate Process for the preparation and use of the preparation

Country Status (30)

Country Link
EP (1) EP1014955B1 (fr)
JP (1) JP2001509812A (fr)
KR (1) KR100528415B1 (fr)
CN (1) CN1195507C (fr)
AT (1) ATE263552T1 (fr)
AU (1) AU728768B2 (fr)
BE (1) BE1012009A5 (fr)
BR (1) BR9806893A (fr)
CA (1) CA2277891C (fr)
CZ (1) CZ295665B6 (fr)
DE (1) DE69823045T2 (fr)
EE (1) EE03950B1 (fr)
ES (2) ES2217535T3 (fr)
FR (1) FR2759905B1 (fr)
GR (1) GR980100023A (fr)
HU (1) HUP0000755A3 (fr)
ID (1) ID21929A (fr)
IE (1) IE980026A1 (fr)
IL (1) IL130839A (fr)
IS (1) IS2072B (fr)
NL (1) NL1008020C2 (fr)
NO (1) NO993540L (fr)
NZ (1) NZ336595A (fr)
PL (1) PL189551B1 (fr)
RU (1) RU2180562C2 (fr)
SE (1) SE9700136D0 (fr)
SK (1) SK283943B6 (fr)
TR (1) TR199901689T2 (fr)
UA (1) UA57765C2 (fr)
WO (1) WO1998031353A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
JP2001151673A (ja) * 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
SE0200657D0 (sv) * 2002-03-04 2002-03-04 Astrazeneca Ab Novel Formulation
GB0219511D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
NZ538965A (en) 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
DE102007049931A1 (de) 2007-10-18 2009-04-23 Pharmatech Gmbh Vorrichtung und Verfahren zur kontinuierlichen Herstellung von sphärischen Pulveragglomeraten
EP2255807A1 (fr) 2009-05-26 2010-12-01 Sanofi-Aventis Procédé de traitement des troubles du sommeil utilisant la combinaison d'éplivanserine et zolpidem
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0072046B1 (fr) * 1981-07-24 1986-01-15 FISONS plc Médicaments pour inhalation, méthodes pour leur production et formulations pharmaceutiques les contenant
ATE17441T1 (de) * 1981-07-24 1986-02-15 Fisons Plc Inhalierbare arzneimittel, verfahren zu deren herstellung und pharmazeutische formulierungen diese enthaltend.
WO1995009615A1 (fr) * 1993-10-01 1995-04-13 Astra Aktiebolag Procede (i)
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination

Also Published As

Publication number Publication date
PL334526A1 (en) 2000-02-28
TR199901689T2 (xx) 1999-09-21
NO993540L (no) 1999-09-20
IS5107A (is) 1999-07-06
EE9900293A (et) 2000-02-15
AU728768B2 (en) 2001-01-18
CA2277891A1 (fr) 1998-07-23
EP1014955A1 (fr) 2000-07-05
EE03950B1 (et) 2003-02-17
CN1195507C (zh) 2005-04-06
BE1012009A5 (fr) 2000-04-04
EP1014955B1 (fr) 2004-04-07
HUP0000755A2 (hu) 2000-10-28
FR2759905A1 (fr) 1998-08-28
FR2759905B1 (fr) 2001-03-09
SE9700136D0 (sv) 1997-01-20
ES2149083A1 (es) 2000-10-16
ES2149083B1 (es) 2001-05-16
NL1008020A1 (nl) 1998-07-22
NL1008020C2 (nl) 2000-01-18
SK96099A3 (en) 2000-01-18
GR980100023A (el) 1998-09-30
JP2001509812A (ja) 2001-07-24
AU5786098A (en) 1998-08-07
CA2277891C (fr) 2006-08-29
UA57765C2 (uk) 2003-07-15
CZ255899A3 (cs) 1999-10-13
HUP0000755A3 (en) 2001-03-28
DE69823045D1 (de) 2004-05-13
PL189551B1 (pl) 2005-08-31
NO993540D0 (no) 1999-07-19
IL130839A0 (en) 2001-01-28
RU2180562C2 (ru) 2002-03-20
CZ295665B6 (cs) 2005-09-14
DE69823045T2 (de) 2004-10-21
ID21929A (id) 1999-08-12
IS2072B (is) 2005-12-15
IE980026A1 (en) 1998-10-07
KR20000070189A (ko) 2000-11-25
BR9806893A (pt) 2000-05-16
ATE263552T1 (de) 2004-04-15
WO1998031353A1 (fr) 1998-07-23
NZ336595A (en) 2001-01-26
KR100528415B1 (ko) 2005-11-15
SK283943B6 (sk) 2004-05-04
CN1244120A (zh) 2000-02-09
ES2217535T3 (es) 2004-11-01

Similar Documents

Publication Publication Date Title
EP1007017B2 (fr) Budesonide / formoterol formulation pour inhalation ayant une masse volumique apparente de 0,30 a 0,36 g/ml, procede de preparation et utilisation de cette formulation
US6199607B1 (en) Formulation for inhalation
EP1019033B1 (fr) Nouvelle formulation pour inhalation ayant une densite en vrac coulee de 0,28 a 0,38 g/ml et contenant du budesonide
EP1009394B1 (fr) Nouvelle formulation pour inhalation ayant une masse volumique de 0,28 a 0,38 g/ml et contenant du formoterol
CA2277891C (fr) Nouvelle formulation pour inhalation ayant une densite en vrac de 0,28 a 0,38 g/ml et contenant du sulfate de terbutaline, procede de preparation et utilisation de cette formulation
US5980949A (en) Formulation for inhalation
JP4512202B6 (ja) ブデソニドを含む0.28から0.38g/MLのかさ密度を有する吸入用新規製剤

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees